Back to the Virtual Exhibit Hall
| ||||
Greg Romano Oncology Account Manager
|
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. In March 2021, AVEO received FDA approval of FOTIVDA® (tivozanib). To learn more about FOTIVDA, visit our website at FOTIVDAHCP.com Social Media Links
| FOTIVDA® (tivozanib) Power You Can Get Comfortable With AVEO Access Center of Excellence
FOTIVDA® (tivozanib) Power You Can Get Comfortable With FOTIVDA 1.34 mg Standard Dose Bottle
A comprehensive program dedicated to providing personalized support to patients and their loved ones throughout the FOTIVDA treatment Journey
Offer/Highlighted Product Link AVEO ACE: Comprehensive Personalized Patient Support
FOTIVDA Patient Experience Program Resources to Help with the Treatment Journey
| ||
